Navidea Biopharmaceuticals Inc EV / EBITDA
Was ist das EV / EBITDA von Navidea Biopharmaceuticals Inc?
EV / EBITDA von Navidea Biopharmaceuticals Inc ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Navidea Biopharmaceuticals Inc
Was macht Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Unternehmen mit ev / ebitda ähnlich Navidea Biopharmaceuticals Inc
- Amigo PLC hat EV / EBITDA von N/A
- Surgalign hat EV / EBITDA von N/A
- Catasys hat EV / EBITDA von N/A
- Goldhills hat EV / EBITDA von N/A
- Just Kitchen hat EV / EBITDA von N/A
- Alternate Health hat EV / EBITDA von N/A
- Navidea Biopharmaceuticals Inc hat EV / EBITDA von N/A
- Tombill Mines hat EV / EBITDA von N/A
- Grand Talents hat EV / EBITDA von N/A
- CV Sciences hat EV / EBITDA von N/A
- Angold Resources hat EV / EBITDA von N/A
- Adamis Pharmaceuticals Corp hat EV / EBITDA von N/A
- Ovid Therapeutics Inc hat EV / EBITDA von N/A